Articles tagged with Colorectal Cancer
Researchers identified fibronectin and smooth muscle actin as associated with resistance to immunotherapy treatment. Cancer-associated fibroblasts produce these proteins, which contribute to the suppression of the anti-tumor immune response.
Breast cancer death rates are predicted to increase in EU patients aged 80 years and older, while falling in all other age groups. This is attributed to a lack of regular screening and access to modern treatments.
Breast and colorectal cancer screening rates have recovered from pandemic-related declines, surpassing pre-pandemic estimates. Cervical cancer screening rates remain below pre-pandemic levels, indicating a persistent trend of declining early-stage diagnoses.
Researchers found that aspirin prevents cancers from spreading by decreasing a clotting factor called thromboxane A2 and releasing T cells from suppression. This discovery could lead to the development of targeted treatments to prevent cancer metastasis, making aspirin potentially less expensive than antibody-based therapies.
The updated recommendations from the US Multi-Society Task Force on Colorectal Cancer aim to achieve a benchmark of 90% exams with adequate bowel preparation. The guidelines focus on optimizing bowel preparation before, during, and after colonoscopy, including patient education, dietary restrictions, and choice of preparation agent.
Researchers identified co-occurring genetic alterations in colorectal and pancreatic cancers that contribute to resistance to KRAS G12C inhibitors. These mutations can lead to poor prognosis and chemotherapy resistance.
Researchers developed a risk-prediction model based on four factors: family history, body mass index, sex, and smoking. A score equal to or greater than 9 indicates an above 14% likelihood of developing cancer or advanced precancerous lesions in adults under 45.
Researchers from the University of Toronto have shown that a low-carb diet can worsen the DNA-damaging effects of certain gut microbes, increasing the risk of colorectal cancer. A unique strain of E. coli bacteria was found to drive polyp growth in the colon when paired with a low-carb diet.
A nationwide study found that patients with alcoholic liver disease have a significantly higher risk of developing colorectal cancer. The study highlights the importance of comprehensive CRC screening and risk stratification based on new consensus-based definitions of liver disease.
Colorectal cancer is a leading cause of mortality in China due to late-stage diagnosis. Emerging non-invasive diagnostic tests, innovative imaging techniques, and AI applications enhance CRC detection and diagnosis. However, expanding accessibility and promoting public awareness remain key challenges.
Researchers have discovered lipid signatures associated with chemotherapy-resistant cells in colorectal cancer. These lipid alterations can serve as prognostic markers and help develop new treatment strategies to restore drug sensitivity.
Insilico Medicine has discovered a potent and selective CDK12/13 dual inhibitor, compound 12b, using AI-powered platforms. The compound shows significant efficacy in breast cancer and AML models without inducing side effects, paving the way for further therapeutic development.
Researchers have discovered several novel downstream p53 targets that could lead to improved cancer therapies. The study highlights the critical role of p53 in preventing cancer and identifies two new genes, ALDH3A1 and NECTIN4, as potential targets for cancer treatment.
Researchers at Pusan National University have developed a novel drug delivery system that uses nanoparticles to target and kill colorectal cancer cells. The system, which involves encapsulating cancer cell-activated nanoconjugates in an alginate matrix, can selectively deliver drugs to tumor cells while minimizing side effects.
Researchers found that a combination of Panitumumab and low-dose Capecitabine is an effective and well-tolerated maintenance regimen for patients with wild-type KRAS metastatic colorectal cancer. The treatment delayed disease progression while managing side effects, improving patients' quality of life.
The Colorectal Cancer Alliance has awarded new grants to researchers, convened top scientists at the Cure CRC Summit, and launched K-SPY, a groundbreaking multi-center platform trial for high-risk colorectal cancer cases. The initiative aims to improve outcomes for millions affected by the disease.
Researchers found that long-term yogurt intake was associated with lower rates of proximal colon cancer positive for Bifidobacterium, a bacterial species found in yogurt. The study showed that higher yogurt consumption over time may protect against colorectal cancer through changes in the gut microbiome.
A phase 2 clinical trial found that a combination of two HER2 inhibitors was more effective and better tolerated than standard EGFR inhibitor-based therapy for patients with HER2-positive metastatic colorectal cancer. The study showed that the level of HER2 amplification in tumors played a key role in determining treatment outcomes.
The study analyzed 63 tumor samples from 10 common malignancies, revealing how malignant cells specialize in growing tumors and non-cancer cells contribute to the immune system's suppression. The findings suggest a hierarchical structure of tumors with specific hallmark expression patterns.
Researchers tracked cfDNA levels before, during, and after colorectal cancer surgery, revealing significant increases associated with age, comorbidities, and surgical manipulation. The study suggests that cfDNA could serve as a non-invasive biomarker to monitor patient outcomes and evaluate surgical effectiveness.
Researchers discover Artemisia herba-alba extract stops cancer cell growth and causes them to die, with potential as a complementary treatment. The study highlights the plant's selective cytotoxicity against CRC cell lines, offering a promising natural ingredient for new cancer treatments.
A blood test using Signatera detected tiny fragments of tumor DNA in the blood, which showed that adding celecoxib to treatment may improve disease-free survival for patients with stage III colon cancer. The analysis found significantly improved outcomes for those taking celecoxib compared to placebo.
Patients with BRAF V600E mutations showed a 60.9% overall response rate to a combination of encorafenib, cetuximab, and mFOLFOX6 chemotherapy, compared to 40% with standard-of-care treatment. This triple-combination therapy offers an effective new first-line treatment option for patients with this mutation.
Researchers identified distinct molecular features of early onset colorectal cancer in racial and ethnic minorities, including widespread changes in DNA methylation and metabolic gene expression. These findings suggest that environmental risk factors such as diet and stress may contribute to the disparities in incidence and mortality a...
A team of researchers at Johns Hopkins Medicine has developed a biomarker algorithm that can detect Barrett’s esophagus and esophageal cancer using a noninvasive method. The algorithm uses methylation patterns in genes to identify biomarkers, achieving an AUC of nearly 0.97 in distinguishing healthy tissue from esophageal cancer.
Researchers at University of Birmingham have discovered three new protein biomarkers TFF3, LCN2, and CEACAM5 that show strong predictive potential for colorectal cancer. These biomarkers are linked to cell adhesion and inflammation, processes closely associated with cancer development.
Researchers at Johns Hopkins Medicine identified a new epigenetic approach to target colorectal cancer, using a mouse protein that disrupts cancer-causing chemical changes in genes. The study found that the protein, STELLA, can be used to develop a drug strategy to treat solid tumors.
A recent NUS Medicine study found that a molecule called DUSP6 plays a major role in helping colorectal cancer grow, with higher levels linked to poorer prognosis and decreased survival. Researchers suggest blocking DUSP6 could lead to new therapies for CRC treatment.
A new study found that Medicare Advantage patients with colorectal cancer are six percentage points less likely to receive a cancer drug compared to those on Traditional Medicare. For non-small cell lung cancer, the pattern was not as clear due to limited low-cost treatment options.
Sylvester Comprehensive Cancer Center offers expert advice on coping with holiday loss and grief. Biological age can predict early colorectal cancer risk, while research advances may lead to a cure for multiple myeloma. Blood cancer experts share insights into new treatments.
A recent study published in The Lancet Oncology reveals a global surge in early-onset colorectal cancer cases, with 27 countries experiencing significant increases in young adults. The research highlights the need for innovative prevention strategies tailored to younger generations and local resources worldwide.
The collaboration aims to evaluate the potential of AMB-066 as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease. MD Anderson researchers have identified a potential opportunity for AMB-066 to effectively treat MRD-positive CRC, based on robust preclinical data.
A new study suggests that a person's biological age can predict their risk of developing colon polyps and early colorectal cancer. Accelerated aging, which is higher than chronological age, may be linked to a greater risk of developing the disease, highlighting the importance of early screening.
Researchers at USF and TGH Cancer Institute found a potential link between the Western diet and chronic inflammation that drives tumor growth. Chronic inflammation fueled by poor dietary choices plays a vital role in colorectal cancer growth and progression.
A study led by UF Health Cancer Center researchers found that a toxin in the bacteria Campylobacter jejuni accelerates the spread of colorectal tumors. The findings could lead to new tools for detecting metastatic colorectal cancer early, ultimately helping determine patients who need more aggressive treatments.
The study estimated that prevention, screening, and treatment efforts in the US led to an average of 8 out of 10 cancer deaths being avoided for breast, cervical, colorectal, lung, and prostate cancers combined. The total number of averted cancer deaths was approximately 5.94 million between 1975 and 2020.
Researchers identify two strains of bacteria producing colibactin as a potential link to colorectal, bladder, and prostate cancers. Targeting these strains with vaccines or probiotics could reduce cancer risk and infection burden.
Researchers found that tumor cell secreted DNA in extracellular vesicles acts as a 'danger' signal to activate an anti-tumor response in the liver, reducing liver metastasis risk. The discovery improves understanding of cancer progression and anticancer immunity.
Researchers urge people to improve their eating habits to reduce the risk of bowel cancer, citing evidence that high-fibre foods promote healthy gut bacteria. Studies found a link between poor diet choices and digestive cancers, highlighting the importance of diets rich in whole grains, vegetables, fruits, and legumes.
The updated ASTRO guideline recommends personalized treatment approaches for patients with locally advanced rectal cancer, including non-surgical alternatives and intensified treatment regimens. The guideline aims to improve outcomes while preserving quality of life.
A new study shows that mailing at-home fecal immunochemical testing kits and providing coordinated follow-up led to a tripling of screening completion rates compared to usual care. The intervention increased screening rates by 30% within six months and 34.6% by 12 months.
A cohort study reveals racial and ethnic variations in early-onset colorectal cancer mortality, with Native Hawaiian or Other Pacific Islander and non-Hispanic Black individuals facing the highest burden. Social determinants of health play a significant role in explaining these disparities.
Researchers sequenced tissue and plasma samples from patients with conventional CRAs to identify genetic alterations. They found that a small proportion of samples successfully detected tissue-origin variants within matched cfDNA. The study also explored the genomic characteristics and progression of cancer from CRA to CRC-I, highlight...
Researchers at Karolinska Institutet have identified a molecule that can promote mucosal healing through tissue regeneration, potentially treating inflammatory bowel disease and colorectal cancer. The study found that activation of the Liver X receptor suppresses tumor growth in colorectal cancer, offering new therapeutic strategies.
Researchers explore potential synergies between chemotherapy, cannabinoids, and intermittent serum starvation in treating colorectal cancer. Combining these therapies could create a strong synergy by depriving cancer cells of glucose, making them more susceptible to treatment.
Researchers at Anglia Ruskin University are investigating the complex relationship between fat tissue and colorectal cancer. The study aims to enhance knowledge of the tumour microenvironment, uncover new molecules crucial for cancer growth, and develop more effective treatments.
Emerging endoscopic technologies, such as wide-field and microscopic-field techniques, enhance CRC screening. AI-driven tools improve polyp detection rates and reduce biopsy rates, while robotic colonoscopy offers procedural precision and patient comfort.
Researchers found higher levels of CD47 expression linked to more aggressive tumors, immune cells, and oncogenic signaling. Targeting CD47 could lead to improved outcomes with immunotherapy drugs, especially in cases where existing treatments are ineffective.
The National Comprehensive Cancer Network has updated its guidelines for genetic/familial high-risk assessment, incorporating the latest scientific research and expert recommendations to enhance screening practices and treatment options. The expanded guidelines cover various cancer types and provide guidance on genetic testing, heredit...
A recent study demonstrates that stool DNA testing is highly sensitive and specific for detecting colorectal cancer among Thai individuals, with a sensitivity of 91.5% and specificity of 90.3%. The test targets methylation statuses of three genes and may provide a viable non-invasive alternative to colonoscopy.
Researchers have discovered a therapeutic approach that shows promise in preclinical models for treating cancers driven by RAS mutations. The study found that tri-complex inhibitors can restore the normal functioning of mutated RAS proteins, aiming to correct the defect that drives cancer growth.
Researchers create genetic barcoding approach to record cellular events and clonality in vivo, revealing that colorectal cancer originates from multiple healthy cells. This work provides a new understanding of the transition from polyclonal to monoclonal composition in advanced stages.
Researchers identified three long noncoding RNAs associated with worse outcomes in colorectal cancer patients, potentially serving as prognostic markers. The study's findings could enable doctors to separate high-risk patients from those at low risk of disease recurrence, leading to more effective treatment strategies.
A recent study by Stanford Medicine suggests that new blood-based colon cancer screening tests are effective for people who shun traditional methods. However, if too many switch to the new tests, colorectal cancer death rates may rise due to reduced detection of early cancers and precancerous polyps.
Researchers have developed a 'mini-protein' that targets cancer cells expressing Nectin-4, allowing for direct delivery of radiation to tumours. The treatment shows promise in targeting multiple types of cancers and has the potential to be safe for repeated administrations.
Researchers have discovered key mutations in certain cancer cells that render WRN inhibitors ineffective. The study found that prolonged exposure to these inhibitors can lead to the acquisition of mutations in the WRN gene, allowing cancer cells to survive and develop resistance.
Researchers developed grain-sized soft robots that can transport up to four different drugs, release them in reprogrammable orders and doses, and navigate complex environments inside the human body. The robots' precision functions have the potential to significantly improve therapeutic outcomes while minimizing side effects.
UTEP researchers developed a portable device that can detect colorectal and prostate cancer quickly and accurately, reducing the need for costly instruments. The device is low-cost, sensitive, and analyzes samples in just an hour.
The Colorectal Cancer Alliance's Project Cure CRC has awarded nearly $5 million in research grants to advance urgent science in colorectal cancer. Recent awardees are working on topics such as radioimmunotherapy, CRISPR technology, and the protein drug ProAgio to better understand and treat this disease.
A new study reveals that high levels of dietary iron from red meat reactivates telomerase, driving colorectal cancer progression. A promising small molecule, SP2509, blocks this reaction, offering hope for targeted therapies in Singapore and globally.